Glioblastoma Multiforme Treatment Market
Glioblastoma Multiforme Treatment Market Analysis by Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy), by Drug Class (Temozolomide, Bevacizumab, Carmustine Wafers), by Application, by Region - Global Market Insights 2022 to 2032
Analysis of Glioblastoma Multiforme Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Glioblastoma Multiforme Treatment Market Outlook (2022 to 2032)
Global sales of the Glioblastoma Multiforme Treatment Market in 2021 was held at US$ 2.6 Billion. With 10.1%, the projected market growth during 2022 to 2032 is expected to be significantly higher than the historical growth.
Radiation Therapy is expected to be the highest revenue generating segment, accounting for an expected CAGR rate of 10.9% during 2022 to 2032.
| Report Attributes | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2017 to 2021 |
| Key Market Segments Covered | Treatment, Drug Class, Application, Region |
| Key Companies Profiled | Merck & Co., Inc.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Amgen, Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, LLC; Amneal Pharmaceuticals; Karyopharm Therapeutics, Inc.; Sumitomo Dainippon Pharma Oncology, Inc. |
Revenue of Glioblastoma Multiforme Treatment Markets from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032
As per the Glioblastoma Multiforme Treatment Markets research by Fact.MR - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the Glioblastoma Multiforme Treatment Markets increased at around 8.1% CAGR.
Glioblastoma multiforme's rising prevalence, more R&D, and favourable regulatory scenarios are among the reasons expected to drive market expansion. Over the forecast period, the rising incidence of brain tumours is expected to enhance market growth.
According to the Global Cancer Observatory, the global incidence of brain and CNS malignancies cases were as high as 308,102 in 2020, with 251,329 fatalities. Glioblastoma multiforme, the most prevalent type of malignant tumour, accounts for around 54% of gliomas and 16% of all primary brain malignancies. Adults have a higher incidence of glioblastoma multiforme than children, and the chance of having the disease increases with age. The rising confirmation that targeted therapy and healing treatment are probable to propel the glioblastoma multiforme drug market in the near-term.
There is greater demand for customized treatments for glioblastoma multiforme vesicles because there are a lot of different approaches to treating it and because each patient will require a different treatment. The approval of new oncology drugs is expected to increase the life expectancy of glioblastoma multiforme patients. Furthermore, the FDA's designation process for new therapy processes is likely to boost the speed of recording new therapies and considerably shorten their cycle to becoming approved and marketed.
- Glioblastoma Multiforme Treatment Market was valued at US$ 2.6 Billion in 2021. According to Fact.MR, Glioblastoma Multiforme Treatment Market revenue would increase 2.8X between 2022 and 2032, reaching roughly US$ 7 Billion by 2032.
- Among treatments, Radiation Therapy accounts for the largest market share with a projected growth rate of 10.9%.
- In terms of Application, revenue through Hospitals is projected to witness highest CAGR of 10.8% during 2022 to 2032.
- North America led the Glioblastoma Multiforme Treatment revenues, with over 40% share.
- The market in US is expected to garner an absolute dollar growth opportunity of US$ 1.8 Bn during 2022 to 2032.
How are the Pipeline Products Expected to Bolster the Growth of Glioblastoma Multiforme Treatment Market?
The existing glioblastoma multiforme treatment provider companies are willing to acquire new companies with pipeline products to diversify their product portfolio. Various initiatives taken by governments and non-government organisations around the world to raise awareness by educating people living with glioblastoma multiforme and further raising funds for R&D activities and treatment; which is expected to drive the market growth during the forecast period.
How are Oncological Diseases responsible for Boosting the Growth of Glioblastoma Multiforme Treatment Market?
Due to tumour heterogeneity and variation in patient-to-patient treatment techniques, the demand for a customised therapeutic method to manage glioblastoma multiforme is expected to grow. Patients with glioblastoma multiforme are likely to live longer as new treatments are approved.
Furthermore, the FDA's special classification for investigational drugs is expected to hasten the approval and marketing of innovative therapeutics. One of the important reasons driving market expansion is the rising frequency of oncological diseases and a growing elderly population around the world. Furthermore, the advancement of improved therapeutic strategies to combat the resistant qualities of glioma stem cells is favourably impacting market growth.
On the other hand, increased R&D operations in molecular biotechnology and gene therapy for cancer and associated diseases have aided the creation of a variety of biological treatments. These medications help to reduce the negative effects of current treatment modalities, allowing patients to accept them more readily. Besides, actions taken by several governments around the world to improve healthcare infrastructure as well as increased awareness of the availability of various therapies, are projected to boost the market's prospects.
Which Region is projected to Offer the Largest Opportunity for Glioblastoma Multiforme Treatment Market?
In 2021, with over 40% share North America held the largest share of glioblastoma treatment market. Government support for the healthcare sector's development, high level of awareness about rare disorders, easy access to high-quality medical facilities, and attractive reimbursement policies are some of the important drivers driving regional market growth.
Why Glioblastoma Treatment Market in Asia-Pacific is projected to Grow at Fastest Pace in the Next 10 Years?
Due to several factors such as the introduction of generic temozolomide, the improving regional economy, growing geriatric population, and increased healthcare investment, the market in Asia Pacific is expected to grow at the fastest rate throughout the projection period. The presence of substantial unmet demands in the market, rising awareness of glioblastoma multiforme treatment, and a robust pipeline are all contributing to regional market growth.
Country-wise Analysis
Which Country Lies at the CenterStage for Glioblastoma Multiforme Treatment Market Revenue?
The United States is expected to have the largest revenue of US$ 2.9 Billion by the end of 2032. In recent years, the industry has been growing rapidly owing to support from the healthcare governing authorities in the country.
For instance, in October 2019, the FDA granted Denovo Biopharma, a San Diego-based biotech company, clearance for its phase 2b clinical trial assessing an analytical combination medication for the treatment of newly diagnosed glioblastoma multiforme patients in October 2019. Their DB102 therapy has been cleared for a study to see how effective it is when used in conjunction with temozolomide (Temodar) and radiation.
Category-wise Insights
Why Radiation Therapy Leads the Glioblastoma Multiforme Treatment Revenues?
Among treatments, revenue through Radiation Therapy is expected to have the highest CAGR of 10.7%. Radiation therapy can be used as a stand-alone treatment or in conjunction with chemotherapy and surgery. In the event of a recurrence of brain tumour, it is also beneficial and highly recommended. When temozolomide is used with radiotherapy, the tumour becomes more sensitive to radiation. Thus the combination of treatments is more successful than radiotherapy alone.
The most common treatment for GBM is surgery, which is followed by radiation therapy and chemotherapy. This treatment regimen is widely considered as gold standard. In addition, the growing usage of targeted therapy to treat glioblastoma multiforme treatment is likely to drive segment growth throughout the projection period. Besides, rising research initiatives to find novel targeted therapies for the condition are expected to propel the segment forward.
Increases in patient-centric, non-invasive therapies, such as external beam radiation therapy and tumor-associated therapies, are anticipated to fuel the growth of the medical treatment service industry. For example, the delivery of treatment for brain tumors at Johns Hopkins Medicine integrates technologies such as radiation therapy, tumor-treating field therapy, and other approaches.
Why Hospitals are Projected to Account for Nearly Half of the Absolute $ Opportunity of Glioblastoma Multiforme Treatment Market?
Revenue through Hospitals is expected to account for over half of the Glioblastoma Multiforme Treatment market by 2032, with an astounding forecast CAGR of 12%. Hospitals are preferred by patients in terms of treatment accessibility and convenience. Moreover, the high number of surgeries performed to manage glioblastoma multiforme treatment and the complexity associated with the treatment are anticipated to drive the market.
How Has COVID-19 Impacted Revenue Generation from Glioblastoma Multiforme Treatment Market?
The unexpected breakout of COVID-19 around the globe has had a significant influence on the treatment of recurrent glioblastoma multiforme and other malignancies. Patients were unable to get radiotherapy, chemotherapy, or health monitoring in health and surgery centers. The pandemic also damaged the worldwide pharmaceutical supply chain, making treatment for patients with recurrent glioblastoma multiforme more difficult to get.
Competitive Analysis
To obtain a competitive advantage, key companies in the glioblastoma multiforme treatment market are focused on R&D to offer distinguished services. Besides, mergers and acquisitions, as well as licencing and collaborations, are being pursued by the key companies in order to increase their product portfolio, extend their manufacturing facilities, and create competitive distinctiveness.
Some of the key players operating in glioblastoma multiforme treatment market include Merck & Co., Inc., Amgen, Inc.,F. Hoffmann-La Roche Ltd.,Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals,Karyopharm Therapeutics, Inc., and Sumitomo Dainippon Pharma Oncology, Inc.
Some of the recent developments of key Glioblastoma Multiforme Treatment providers are as follows:
- In April 2021, Lineage Cell Therapeutics made a licensing agreement with Immunomic Therapeutics to develop allogeneic VAC, a cancer immunotherapy platform, to treat glioblastoma multiforme. Under the agreement terms, Lineage will receive a US$ 2 Mn upfront payment, followed by US$ 67 Mn in commercial milestone payments.
- In July 2020, Denovo Biopharma, a San Diego-based biotech company, was granted the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical trial evaluating an analytical combination therapy for the treatment of newly diagnosed glioblastoma multiforme patients.
- In May 2019, Merck announced the acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.
Similarly, recent developments related to companies offering Glioblastoma Multiforme Treatment have been tracked by the team at Fact.MR, which are available in the full report.
Market Segments Covered in Glioblastoma Multiforme Treatment Market Analysis
-
By Treatment :
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Tumor Treating Field (TTF) Therapy
- Immunotherapy
-
By Drug Class :
- Temozolomide
- Bevacizumab
- Carmustine Wafers
- Other Drug Classes
- Lomustine
-
By Application :
- Hospitals
- Clinics
- Ambulatory Surgical Centers
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Risks and Trends Assessment
- 4. Market Background
- 5. Key Success Factors
- 6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032
- 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment
- 8.1. Surgery
- 8.2. Radiation Therapy
- 8.3. Chemotherapy
- 8.4. Targeted Therapy
- 8.5. Tumor Treating Field (TTF) Therapy
- 8.6. Immunotherapy
- 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Class
- 9.1. Temozolomide
- 9.2. Bevacizumab
- 9.3. Lomustine
- 9.4. Carmustine Wafers
- 9.5. Other Drug Classes
- 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
- 10.1. Hospitals
- 10.2. Ambulatory Surgery Centers
- 10.3. Clinics
- 11. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Europe
- 11.4. Asia Pacific
- 11.5. Middle East and Africa (MEA)
- 12. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 13. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 14. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 15. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 16. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 17. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032
- 18. Market Structure Analysis
- 19. Competition Analysis
- 19.1. Merck & Co. Inc.
- 19.2. Sumitomo Dainippon Pharma Oncology Inc
- 19.3. Teva Pharmaceutical Industries Ltd
- 19.4. Sun Pharmaceutical Industries Ltd
- 19.5. F. Hoffmann-La Roche Ltd.
- 19.6. Karyopharm Therapeutics, Inc.
- 20. Assumptions and Acronyms Used
- 21. Research Methodology
List Of Table
Table 1: Global Market Value (US$ Bn), By Treatment, 2017 to 2021
Table 2: Global Market Value (US$ Bn), By Treatment, 2022 to 2032
Table 3: Global Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 4: Global Market Value (US$ Bn), By Application, 2022 to 2032
Table 5: Global Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 6: Global Market Value (US$ Bn), By Drug Class, 2022 to 2032
Table 7: Global Market, By Region, 2017 to 2021
Table 8: Global Market, By Region, 2022 to 2032
Table 9: North America Market Value (US$ Bn), By Treatment, 2017 to 2021
Table 10: North America Market Value (US$ Bn), By Treatment, 2022 to 2032
Table 11: North America Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 12: North America Market Value (US$ Bn), By Application, 2022 to 2032
Table 13: North America Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 14: North America Market Value (US$ Bn), By Drug Class, 2022 to 2032
Table 15: North America Market, By Country, 2017 to 2021
Table 16: North America Market, By Country, 2022 to 2032
Table 17: Latin America Market Value (US$ Bn), By Treatment, 2017 to 2021
Table 18: Latin America Market Value (US$ Bn), By Treatment, 2022 to 2032
Table 19: Latin America Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 20: Latin America Market Value (US$ Bn), By Application, 2022 to 2032
Table 21: Latin America Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 22: Latin America Market Value (US$ Bn), By Drug Class, 2022 to 2032
Table 23: Latin America Market, By Country, 2017 to 2021
Table 24: Latin America Market, By Country, 2022 to 2032
Table 25: Europe Market Value (US$ Bn), By Treatment, 2017 to 2021
Table 26: Europe Market Value (US$ Bn), By Treatment, 2022 to 2032
Table 27: Europe Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 28: Europe Market Value (US$ Bn), By Application, 2022 to 2032
Table 29: Europe Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 30: Europe Market Value (US$ Bn), By Drug Class, 2022 to 2032
Table 31: Europe Market, By Country, 2017 to 2021
Table 32: Europe Market, By Country, 2022 to 2032
Table 33: Asia Pacific Market Value (US$ Bn), By Treatment, 2017 to 2021
Table 34: Asia Pacific Market Value (US$ Bn), By Treatment, 2022 to 2032
Table 35: Asia Pacific Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 36: Asia Pacific Market Value (US$ Bn), By Application, 2022 to 2032
Table 37: Asia Pacific Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 38: Asia Pacific Market Value (US$ Bn), By Drug Class, 2022 to 2032
Table 39: Asia Pacific Market, By Country, 2017 to 2021
Table 40: Asia Pacific Market, By Country, 2022 to 2032
Table 41: MEA Market Value (US$ Bn), By Treatment, 2017 to 2021
Table 42: MEA Market Value (US$ Bn), By Treatment, 2022 to 2032
Table 43: MEA Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 44: MEA Market Value (US$ Bn), By Application, 2022 to 2032
Table 45: MEA Market Value (US$ Bn), By Drug Class, 2017 to 2021
Table 46: MEA Market Value (US$ Bn), By Drug Class, 2022 to 2032
Table 47: MEA Market, By Country, 2017 to 2021
Table 48: MEA Market, By Country, 2022 to 2032
Table 49: Global Market Incremental $ Opportunity, By Treatment, 2017 to 2021
Table 50: Global Market Incremental $ Opportunity, By Drug Class, 2022 to 2032
Table 51: Global Market Incremental $ Opportunity, By Drug Class, 2017 to 2021
Table 52: Global Market Incremental $ Opportunity, By Region, 2022 to 2032
Table 53: North America Market Incremental $ Opportunity, By Treatment, 2017 to 2021
Table 54: North America Market Incremental $ Opportunity, By Application, 2022 to 2032
Table 55: North America Market Incremental $ Opportunity, By Drug Class, 2017 to 2021
Table 56: North America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 57: Latin America Market Incremental $ Opportunity, By Treatment, 2017 to 2021
Table 58: Latin America Market Incremental $ Opportunity, By Drug Class, 2022 to 2032
Table 59: Latin America Market Incremental $ Opportunity, By Drug Class, 2017 to 2021
Table 60: Latin America Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 61: Europe Market Incremental $ Opportunity, By Treatment, 2017 to 2021
Table 62: Europe Market Incremental $ Opportunity, By Application, 2022 to 2032
Table 63: Europe Market Incremental $ Opportunity, By Drug Class, 2017 to 2021
Table 64: Europe Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 65: Asia Pacific Market Incremental $ Opportunity, By Treatment, 2017 to 2021
Table 66: Asia Pacific Market Incremental $ Opportunity, By Drug Class, 2022 to 2032
Table 67: Asia Pacific Market Incremental $ Opportunity, By Drug Class, 2017 to 2021
Table 68: Asia Pacific Market Incremental $ Opportunity, By Country, 2022 to 2032
Table 69: MEA Market Incremental $ Opportunity, By Treatment, 2017 to 2021
Table 70: MEA Market Incremental $ Opportunity, By Application, 2022 to 2032
Table 71: MEA Market Incremental $ Opportunity, By Drug Class, 2017 to 2021
Table 72: MEA Market Incremental $ Opportunity, By Country, 2022 to 2032
List Of Figures
Figure 1: Global Market Value (US$ Bn) and Year-on-Year Growth, 2017 to 2032
Figure 2: Global Market Absolute $ Historical Gain (2017 to 2021) and Opportunity (2022 to 2032), US$ Bn
Figure 3: Global Market Share, By Treatment, 2022 & 2032
Figure 4: Global Market Y-o-Y Growth Projections, By Treatment– 2022 to 2032
Figure 5: Global Market Attractiveness Index, By Treatment– 2022 to 2032
Figure 6: Global Market Share, By Drug Class, 2022 & 2032
Figure 7: Global Market Y-o-Y Growth Projections, By Application– 2022 to 2032
Figure 8: Global Market Attractiveness Index, By Drug Class– 2022 to 2032
Figure 9: Global Market Share, By Drug Class, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth Projections, By Application – 2022 to 2032
Figure 11: Global Market Attractiveness Index, By Drug Class – 2022 to 2032
Figure 12: Global Market Share, By Region, 2022 & 2032
Figure 13: Global Market Y-o-Y Growth Projections, By Region – 2022 to 2032
Figure 14: Global Market Attractiveness Index, By Region – 2022 to 2032
Figure 15: North America Market Value (US$ Bn) and Year-on-Year Growth, 2017 to 2032
Figure 16: North America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Bn
Figure 17: North America Market Share, By Treatment, 2022 & 2032
Figure 18: North America Market Y-o-Y Growth Projections, By Treatment– 2022 to 2032
Figure 19: North America Market Attractiveness Index, By Treatment– 2022 to 2032
Figure 20: North America Market Share, By Application, 2022 & 2032
Figure 21: North America Market Y-o-Y Growth Projections, By Drug Class– 2022 to 2032
Figure 22: North America Market Attractiveness Index, By Application– 2022 to 2032
Figure 23: North America Market Share, By Drug Class, 2022 & 2032
Figure 24: North America Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 25: North America Market Attractiveness Index, By Application – 2022 to 2032
Figure 26: North America Market Share, By Country, 2022 & 2032
Figure 27: North America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 28: North America Market Attractiveness Index, By Country – 2022 to 2032
Figure 29: Latin America Market Value (US$ Bn) and Year-on-Year Growth, 2017 to 2032
Figure 30: Latin America Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Bn
Figure 31: Latin America Market Share, By Treatment, 2022 & 2032
Figure 32: Latin America Market Y-o-Y Growth Projections, By Treatment– 2022 to 2032
Figure 33: Latin America Market Attractiveness Index, By Treatment– 2022 to 2032
Figure 34: Latin America Market Share, By Drug Class, 2022 & 2032
Figure 35: Latin America Market Y-o-Y Growth Projections, By Application– 2022 to 2032
Figure 36: Latin America Market Attractiveness Index, By Drug Class– 2022 to 2032
Figure 37: Latin America Market Share, By Drug Class, 2022 & 2032
Figure 38: Latin America Market Y-o-Y Growth Projections, By Application – 2022 to 2032
Figure 39: Latin America Market Attractiveness Index, By Drug Class – 2022 to 2032
Figure 40: Latin America Market Share, By Country, 2022 & 2032
Figure 41: Latin America Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 42: Latin America Market Attractiveness Index, By Country – 2022 to 2032
Figure 43: Europe Market Value (US$ Bn) and Year-on-Year Growth, 2017 to 2032
Figure 44: Europe Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Bn
Figure 45: Europe Market Share, By Treatment, 2022 & 2032
Figure 46: Europe Market Y-o-Y Growth Projections, By Treatment– 2022 to 2032
Figure 47: Europe Market Attractiveness Index, By Treatment– 2022 to 2032
Figure 48: Europe Market Share, By Application, 2022 & 2032
Figure 49: Europe Market Y-o-Y Growth Projections, By Drug Class– 2022 to 2032
Figure 50: Europe Market Attractiveness Index, By Application– 2022 to 2032
Figure 51: Europe Market Share, By Drug Class, 2022 & 2032
Figure 52: Europe Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 53: Europe Market Attractiveness Index, By Application – 2022 to 2032
Figure 54: Europe Market Share, By Country, 2022 & 2032
Figure 55: Europe Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 56: Europe Market Attractiveness Index, By Country – 2022 to 2032
Figure 57: MEA Market Value (US$ Bn) and Year-on-Year Growth, 2017 to 2032
Figure 58: MEA Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Bn
Figure 59: MEA Market Share, By Treatment, 2022 & 2032
Figure 60: MEA Market Y-o-Y Growth Projections, By Treatment– 2022 to 2032
Figure 61: MEA Market Attractiveness Index, By Treatment– 2022 to 2032
Figure 62: MEA Market Share, By Drug Class, 2022 & 2032
Figure 63: MEA Market Y-o-Y Growth Projections, By Application– 2022 to 2032
Figure 64: MEA Market Attractiveness Index, By Drug Class– 2022 to 2032
Figure 65: MEA Market Share, By Drug Class, 2022 & 2032
Figure 66: MEA Market Y-o-Y Growth Projections, By Application – 2022 to 2032
Figure 67: MEA Market Attractiveness Index, By Drug Class – 2022 to 2032
Figure 68: MEA Market Share, By Country, 2022 & 2032
Figure 69: MEA Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 70: MEA Market Attractiveness Index, By Country – 2022 to 2032
Figure 71: Asia Pacific Market Value (US$ Bn) and Year-on-Year Growth, 2017 to 2032
Figure 72: Asia Pacific Market Absolute $ Opportunity Historical (2017 to 2021) and Forecast Period (2022 to 2032), US$ Bn
Figure 73: Asia Pacific Market Share, By Treatment, 2022 & 2032
Figure 74: Asia Pacific Market Y-o-Y Growth Projections, By Treatment– 2022 to 2032
Figure 75: Asia Pacific Market Attractiveness Index, By Treatment– 2022 to 2032
Figure 76: Asia Pacific Market Share, By Application, 2022 & 2032
Figure 77: Asia Pacific Market Y-o-Y Growth Projections, By Drug Class– 2022 to 2032
Figure 78: Asia Pacific Market Attractiveness Index, By Application– 2022 to 2032
Figure 79: Asia Pacific Market Share, By Drug Class, 2022 & 2032
Figure 80: Asia Pacific Market Y-o-Y Growth Projections, By Drug Class – 2022 to 2032
Figure 81: Asia Pacific Market Attractiveness Index, By Application – 2022 to 2032
Figure 82: Asia Pacific Market Share, By Country, 2022 & 2032
Figure 83: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2022 to 2032
Figure 84: Asia Pacific Market Attractiveness Index, By Country – 2022 to 2032
Figure 85: US Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 86: US Market Share, By Treatment, 2021
Figure 87: US Market Share, By Drug Class, 2021
Figure 88: US Market Share, By Drug Class, 2021
Figure 89: Canada Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 90: Canada Market Share, By Treatment, 2021
Figure 91: Canada Market Share, By Application, 2021
Figure 92: Canada Market Share, By Drug Class, 2021
Figure 93: Brazil Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 94: Brazil Market Share, By Treatment, 2021
Figure 95: Brazil Market Share, By Drug Class, 2021
Figure 96: Brazil Market Share, By Drug Class, 2021
Figure 97: Mexico Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 98: Mexico Market Share, By Treatment, 2021
Figure 99: Mexico Market Share, By Application, 2021
Figure 100: Mexico Market Share, By Drug Class, 2021
Figure 101: Germany Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 102: Germany Market Share, By Treatment, 2021
Figure 103: Germany Market Share, By Drug Class, 2021
Figure 104: Germany Market Share, By Drug Class, 2021
Figure 105: U.K. Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 106: U.K. Market Share, By Treatment, 2021
Figure 107: U.K. Market Share, By Application, 2021
Figure 108: U.K. Market Share, By Drug Class, 2021
Figure 109: France Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 110: France Market Share, By Treatment, 2021
Figure 111: France Market Share, By Drug Class, 2021
Figure 112: France Market Share, By Drug Class, 2021
Figure 113: Italy Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 114: Italy Market Share, By Treatment, 2021
Figure 115: Italy Market Share, By Application, 2021
Figure 116: Italy Market Share, By Drug Class, 2021
Figure 117: India Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 118: India Market Share, By Treatment, 2021
Figure 119: India Market Share, By Drug Class, 2021
Figure 120: India Market Share, By Drug Class, 2021
Figure 121: Russia Countries Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 122: Russia Countries Market Share, By Treatment, 2021
Figure 123: Russia Countries Market Share, By Application, 2021
Figure 124: Russia Countries Market Share, By Drug Class, 2021
Figure 125: China Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 126: China Market Share, By Treatment, 2021
Figure 127: China Market Share, By Drug Class, 2021
Figure 128: China Market Share, By Drug Class, 2021
Figure 129: Japan Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 130: Japan Market Share, By Treatment, 2021
Figure 131: Japan Market Share, By Application, 2021
Figure 132: Japan Market Share, By Drug Class, 2021
Figure 133: South Korea Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 134: South Korea Market Share, By Treatment, 2021
Figure 135: South Korea Market Share, By Drug Class, 2021
Figure 136: South Korea Market Share, By Drug Class, 2021
Figure 137: Spain Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 138: Spain Market Share, By Treatment, 2021
Figure 139: Spain Market Share, By Application, 2021
Figure 140: Spain Market Share, By Drug Class, 2021
Figure 141: South Africa Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 142: South Africa Market Share, By Treatment, 2021
Figure 143: South Africa Market Share, By Drug Class, 2021
Figure 144: South Africa Market Share, By Drug Class, 2021
Figure 145: Saudi Arabia Market Value (US$ Bn) and Forecast, 2022 to 2032
Figure 146: Saudi Arabia Market Share, By Treatment, 2021
Figure 147: Saudi Arabia Market Share, By Application, 2021
Figure 148: Saudi Arabia Market Share, By Drug Class, 2021
- FAQs -
How much is the current worth of the Glioblastoma Multiforme Treatment Market?
The global Glioblastoma Multiforme Treatment Market is worth more than US$ 2.6 Billion at present.
What is the sales forecast for Glioblastoma Multiforme Treatment Market?
The value of Glioblastoma Multiforme Treatment Market is projected to increase at a CAGR of around 10.1% during 2022 – 2032.
What is a key trend shaping the growth of the market for Glioblastoma Multiforme Treatment Market?
The increasing approval for novel therapy and combination therapy is expected to increase the life expectancy of patients living with glioblastoma multiforme. This is consequently expected to impact the glioblastoma multiforme treatment market.
At what percentage is revenue of Glioblastoma Multiforme Treatment Market going to register growth in China?
The market for Glioblastoma Multiforme Treatment Market in China is projected to expand at a CAGR of around 10.5% during 2022 – 2032.
What do statistics for South Korea and Japan reveal?
While the market in South Korea is expected to grow at nearly 10.7%, the market in Japan is projected to register a CAGR of nearly 12.8% during 2022 - 2032.
What was the last 5 year’s market CAGR?
The value of Glioblastoma Multiforme Treatment Market increased at a CAGR of around 8.1% during 2017 – 2021.
Glioblastoma Multiforme Treatment Market